Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins

AIM: To assess the impact of re-biopsy on partially sampled melanoma in situ (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma. MATERIALS & METHODS: We retrospectively identified cases of re-biopsied partially sampled neoplasms initially diagnosed as melanoma in situ, AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitman, Evan S, Perez, Matthew C, Lee, Daniel, Kim, Youngchul, Fulp, William, Sondak, Vernon K, Sarnaik, Amod A, Gonzalez, Ricardo J, Cruse, Carl W, Messina, Jane L, Zager, Jonathan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688556/
https://www.ncbi.nlm.nih.gov/pubmed/31406562
http://dx.doi.org/10.2217/mmt-2018-0011
Descripción
Sumario:AIM: To assess the impact of re-biopsy on partially sampled melanoma in situ (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma. MATERIALS & METHODS: We retrospectively identified cases of re-biopsied partially sampled neoplasms initially diagnosed as melanoma in situ, AMP or thin melanoma (Breslow depth ≤0.75 mm). RESULTS & CONCLUSION: Re-biopsy led to sentinel lymph node biopsy (SLNB) in 18.3% of cases. No patients upstaged from AMP or MIS had a positive SLNB. One out of nine (11.1%) initially diagnosed as a thin melanoma ≤0.75 mm, upstaged with a re-biopsy, had a positive SLNB. After re-biopsy 8.5% underwent an increased surgical margin. Selective re-biopsy of partially sampled melanoma with gross residual disease can increase the accuracy of microstaging and optimize treatment regarding surgical margins and SLNB.

Ejemplares similares